This is the authors' abstract. We don't add key points for this paper.
This article provides a brief overview of the use and recent developments of injectable radiopharmaceuticals for nuclear imaging and therapy. Some up-to-date advances in the field of nuclear medicine include multi-modal molecular imaging probes for image-guided surgery, radiotracers for targeted imaging of cancer and neurodegenerative diseases, as well as probes for monitoring therapy responses. Other exciting improvements in therapeutic radiopharmaceuticals have been demonstrated by novel radioimmunotherapy and peptide receptor radionuclide therapy agents for neuroendocrine tumours. There are active pre-clinical research and clinical trials in developing new radiopharmaceuticals with higher targeting specificity or better therapeutic efficacy. This steady progress is expected to continue and eventually will benefit the general public to an increasing extent.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhengtao Qin (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: